Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Gene Therapy – Access & Reimbursement – Rare Diseases and Orphan Drugs – Top Five European Markets
MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of rare diseases treatment, and ongoing industry focus are key drivers of growth in…
Graft-Versus-Host Disease | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019
GVHD is a potentially life-threatening complication of allogenic HCST. GVHD is a systemic inflammatory reaction triggered by donor T cells’ recognition of host cell antigens in nontarget tissue…
Malignant Melanoma | Unmet Need | BRAF-mutation-positive Unresectable or Metastatic | US/EU | 2019
Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of several combination regimens that include BRAF and MEK inhibitors, as…
Metabolic Dysfunction-Associated Steatohepatitis – Access & Reimbursement – Access & Reimbursement – Nonalcoholic Steatohepatitis in the Top 5 European Markets
MARKET OUTLOOKNon-alcoholic steatohepatitis (NASH) is rapidly becoming an important public health issue in the top five European markets (France, Germany, Italy, Spain, UK). High prevalence of this…